MCM
HAE icon

MV Capital Management’s Haemonetics HAE Stock Holding History

MV Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-46
Closed -$6K – 381
2019
Q3 		$6K Hold
46
– – ﹤0.01% 274
2019
Q2 		$6K Sell
46
-35
-43% -$3.44K ﹤0.01% 267
2019
Q1 		$7K Buy
+81
New +$7.37K ﹤0.01% 259
2018
Q4 		– Sell
-82
Closed -$9K – 337
2018
Q3 		$9K Buy
+82
New +$8.49K ﹤0.01% 252

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MV Capital Management's HAE Position: Q4 2019 in Review

MV Capital Management sold out of Haemonetics (HAE) in Q4 2019, closing a stake of 46 shares — an estimated $6K sold.

MV Capital Management first reported a position in HAE in Q3 2018 and held it in 4 quarters. The position peaked at $9K in Q3 2018. 298 funds tracked by Wall St. Rank hold HAE as of Q4 2019.

  • MV Capital Management reported no remaining Haemonetics position as of Q4 2019 after selling out during the quarter.
  • MV Capital Management sold 46 Haemonetics shares in Q4 2019, an estimated $6K.
  • MV Capital Management first reported a position in Haemonetics in Q3 2018 and held it in 4 quarters.
  • MV Capital Management's Haemonetics position peaked at $9K in Q3 2018.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q4 2019.

Based on MV Capital Management's 13F filing for Q4 2019, filed 5 Feb 2020.